English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/40002
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

TWIST1 is expressed in colorectal carcinomas and predicts patient survival

AuthorsGómez, Irene; Larriba, María Jesús ; García de Herreros, Antonio; Bonilla, Félix; García, José M.
KeywordsEpithelial-mesenchymal transition
Transcription factor snail
E-cadherin expression
Breast-cancer cells
Colon-cancer
Issue Date28-Mar-2011
PublisherPublic Library of Science
CitationPLoS ONE 6(3): e18023 (2011)
AbstractTWIST1 is a transcription factor that belongs to the family of basic helix-loop-helix proteins involved in epithelial-to-mesenchymal transition and invasion processes. The TWIST1 protein possesses oncogenic, drug-resistant, angiogenic and invasive properties, and has been related with several human tumors and other pathologies. Colorectal cancer is one of the tumors in which TWIST1 is over-expressed, but its involvement in the clinical outcome of the disease is still unclear. We tested, by RT-PCR, the expression levels of TWIST1 in normal and tumor paired-sample tissues from a series of 151 colorectal cancer patients, in order to investigate its prognostic value as a tumor marker. TWIST1 expression was restricted to tumor tissues (86.1%) and correlated with lymph node metastasis (LNM). Adjusted analysis showed that the expression levels of TWIST1 correlated with overall survival (OS) and disease-free survival (DFS). Importantly, TWIST1 expression levels predicted OS specifically at stages I and II. Moreover, patients with stage II tumors and high TWIST1 levels showed even shorter survival than patients with stage III tumors. These results suggest that TWIST1 expression levels could be a tumor indicator in stage II patients and help select patients at greater risk of poor prognosis who might benefit from adjuvant chemotherapy.
DescriptionThis is an open-access article distributed under the terms of the Creative Commons Attribution License.-- et al.
Publisher version (URL)http://dx.doi.org/10.1371/journal.pone.0018023
URIhttp://hdl.handle.net/10261/40002
DOI10.1371/journal.pone.0018023
ISSN1932-6203
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
TWIST1.pdf450,21 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.